Book of Abstracts - New Frontiers 2022

Abstracts of oral presentations

CARDIOPROTECTION BY microRNA THERAPEUTICS

P. Ferdinandy 1,2

1 Semmelweis University, Budapest, Hungary; 2 Pharmahungary Group, Szeged, Hungary

Ischemic heart disease is a leading cause of mortality worldwide, therefore, identification of valid drug targets for cardioprotection is of great importance. The lack of successful translation of cardioprotection to clinical therapy after more than 3 decades of intensive research urge the need for novel therapeutics to treat this disease with molecular mechanisms. Indeed major cardiovascular comorbidities such as hyperlipidemia, diabetes, and their co-medications have been shown to interfere with most of the known cardioprotective mechanisms (see for reviews: Ferdinandy et al, Pharmacol Rev , 2014; 2022 upcoming) and to lead to manifestation of hidden cardiotoxicy of drugs (Ferdinandy et al, Eur Heart J , 2019; Brenner et al, Cells , 2020). Cardioprotectionand cardiotoxicity have been shown to affect global myocardial gene expression profile showing that cardioprotectionand cardiotoxicity trigger a complex network of signaling cascade rather than a single major pathway. Moreover, cardiovascular comorbidities have been also shown to affect global cardiac gene expression profile at the transcript level including the non-coding RNAmicroRNAs (Perrino et al, Cardiovasc Res , 2017; Makkos et al, Free Rad Biol Med, 2021). MicroRNS are found in all tissues and body fluids carried by extracellular vesicles (Slujiter et al, Cardiovasc Res , 2018), therefore, microRNA transcriptomics-based target identification may lead to development of novel microRNA therapeutics and diagnostics for cardioprotection against ischemic heart disease and cardiotoxicity.

27